Unbiased and Practical Psychopharmacology Updates

RECENT PUBLICATIONS

2026 August Update: Centanafadine, Oveporexton, and New Guidance on OCD, Lithium, and Insomnia

0.75 CMEs
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Thyroid Issues in Psychiatry – Interview

No Credits
To Be Announced

Quick Take Vol. 90

0.75 CMEs
Does prenatal antidepressant exposure cause autism or ADHD in offspring? How do you weigh cardiac risk when combining an antipsychotic and SSRI? When should you rechallenge a patient with clozapine after neutropenia? Should schizophrenia be renamed? Does adding ashwagandha to melatonin improve sleep more than either agent alone?
Faculty: Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D., Amanda Koire, M.D., Ph.D., Scott R. Beach, M.D.
47.15 minutes in 5 audio sections

Pharmacotherapy of Chronic Insomnia: A Practical Guide

1.0 CMEs
A practical guide to the pharmacological management of chronic insomnia. Dr. Kolla reviews dual orexin receptor antagonists, Z-drugs, benzodiazepines, melatonin and ramelteon, sedating antidepressants, and antipsychotics, with guidance for pregnancy, older adults, and long-term use.
Bhanu Prakash Kolla, M.D.
Mayo Clinic
55.07 minutes in 11 sections

Pharmacotherapy of Difficult-to-Treat Depression: Selection, Switching, Augmentation, and Escalation – Interview

0.50 CMEs
A discussion with Dr. Thase spanning the full treatment hierarchy for treatment-resistant and difficult-to-treat depression, from first-line antidepressant selection and switch versus augment decisions through second-generation antipsychotic augmentation, the impact of psychiatric comorbidities, and interventional options including TMS, ketamine, esketamine, and emerging psychedelic therapies.
Prof. Michael E. Thase, M.D.
Perelman School of Medicine of the University of Pennsylvania – Corporal Michael J. Crescenz Veterans Affairs Medical Center
36.52 minutes of audio interview

Antidepressant-Induced Hyponatremia: Mechanisms, Risk, Diagnosis and Management

0.50 CMEs
This guide gives prescribers an evidence-based approach to antidepressant-associated hyponatremia: how the syndrome of inappropriate antidiuresis (SIAD) develops, which patients to monitor and when, how to recognize symptoms that may mimic depression, and how to manage and apply switching strategies afterward.
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Explore our library of over 480 video lectures, podcasts, research summaries, and expert interviews.

CME Information

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

All of our content is psychopharmacology, so the pharmacology hours shown on your certificate match the credits awarded for that activity. Your certificate states them on their own line, separately from the credit designation statement.

This applies to APRN pharmacology renewal as well. Boards of nursing define pharmacology CE in their own way, so please confirm with your board that this is the documentation they expect.

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide AMA PRA Category 1 Credits™ for physicians.

This CME program issues AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Physicians outside the United States – CME Accreditation Statement

AMA PRA Category 1 Credit™ may be awarded to any physician, whether or not they are licensed in the United States. The requirements are the same.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

Whether these credits count toward your own national continuing education requirement is decided by your national medical chamber or society, and the rules differ from country to country. We recommend confirming with them before relying on the credits for a licensing or recertification requirement.

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

Lost as a newly-matched psychiatry resident?

Access ALL our products FREE for 3 months!